Boyoung Jeong

Title: Boyoung Jeong: Innovator in Human Antibody Development

Introduction

Boyoung Jeong is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of human antibodies. His work focuses on creating innovative solutions that can have a profound impact on medical treatments.

Latest Patents

Boyoung Jeong holds a patent for a human antibody specific to c-Met and its preparation method. This patent describes an antibody that specifically binds to c-Met, which is crucial for various biological processes. The invention includes a fully human antibody with high affinity and specificity to c-Met, isolated from a human Fv(ScFv) phage library. The patent also covers a polynucleotide encoding the antibody, a recombinant vector containing the polynucleotide, and a method for producing the c-Met-specific antibody by culturing transformed cells. This innovation has the potential to effectively control the activity of c-Met in vivo, which could lead to advancements in therapeutic applications.

Career Highlights

Boyoung Jeong is currently associated with Pharmabcine Inc., where he continues to push the boundaries of antibody research. His expertise in the field has positioned him as a key player in the development of novel therapeutic agents. With a focus on human antibodies, he is dedicated to improving treatment options for various diseases.

Collaborations

Throughout his career, Boyoung Jeong has collaborated with notable colleagues, including Jinsang Yoo and Ju Ryoung Nam. These partnerships have fostered a collaborative environment that enhances innovation and research outcomes.

Conclusion

Boyoung Jeong's contributions to the field of biotechnology, particularly in the development of human antibodies, highlight his role as an influential inventor. His patent on the c-Met-specific antibody represents a significant advancement in medical research. Through his work at Pharmabcine Inc. and collaborations with esteemed colleagues, he continues to make strides in improving healthcare solutions.